Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System
Eimeren, Thilo; Antonini, Angelo; Berg, Daniela; Bohnen, Nico; Ceravolo, Roberto; Drzezga, Alexander; Höglinger, Günter U.; Higuchi, Makoto; Lehericy, Stephane; Lewis, Simon; Monchi, Oury; Nestor, Peter; Ondrus, Matej; Pavese, Nicola; Peralta, María Cecilia; Piccini, Paola; Pineda‐pardo, José Ángel; Rektorová, Irena; Rodríguez‐oroz, María; Rominger, Axel; Seppi, Klaus; Stoessl, A. Jon; Tessitore, Alessandro; Thobois, Stephane; Kaasinen, Valtteri; Wenning, Gregor; Siebner, Hartwig R.; Strafella, Antonio P.; Rowe, James B.
2019-12
Citation
Eimeren, Thilo; Antonini, Angelo; Berg, Daniela; Bohnen, Nico; Ceravolo, Roberto; Drzezga, Alexander; Höglinger, Günter U. ; Higuchi, Makoto; Lehericy, Stephane; Lewis, Simon; Monchi, Oury; Nestor, Peter; Ondrus, Matej; Pavese, Nicola; Peralta, María Cecilia ; Piccini, Paola; Pineda‐pardo, José Ángel ; Rektorová, Irena ; Rodríguez‐oroz, María ; Rominger, Axel; Seppi, Klaus; Stoessl, A. Jon; Tessitore, Alessandro; Thobois, Stephane; Kaasinen, Valtteri; Wenning, Gregor; Siebner, Hartwig R.; Strafella, Antonio P.; Rowe, James B. (2019). "Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System." Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 11(C): 301-309.
Abstract
IntroductionTherapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders.MethodsTo promote standardized use of neuroimaging biomarkers for clinical trials, we aimed to develop a conceptual framework to characterize in more detail the kind of neuroimaging biomarkers needed in atypical parkinsonian disorders, identify the current challenges in ascribing utility of these biomarkers, and propose criteria for a system that may guide future studies.ResultsAs a consensus outcome, we describe the main challenges in ascribing utility of neuroimaging biomarkers in atypical parkinsonian disorders, and we propose a conceptual framework that includes a graded system for the description of utility of a specific neuroimaging measure. We included separate categories for the ability to accurately identify an intentionâ toâ treat patient population early in the disease (Early), to accurately detect a specific underlying pathology (Specific), and the ability to monitor disease progression (Progression).DiscussionWe suggest that the advancement of standardized neuroimaging in the field of atypical parkinsonian disorders will be furthered by a wellâ defined reference frame for the utility of biomarkers. The proposed utility system allows a detailed and graded description of the respective strengths of neuroimaging biomarkers in the currently most relevant areas of application in clinical trials.Highlightsâ ¢Challenges in ascribing utility of neuroimaging biomarkers in clinical trials.â ¢Criteria for utility of neuroimaging biomarkers in clinical trials.â ¢Proposition of a formalized and graded utility description system.Publisher
Wiley Periodicals, Inc. Butterworths & Co.
ISSN
2352-8729 2352-8729
Other DOIs
Types
Article
Metadata
Show full item recordCollections
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.